MANIDIPINE 6300

Summary

Manidipine 6300 (CHEMBL1085699) is a phase-3 clinical-stage small molecule (ATC C08CA11); indicated across 2 conditions including cardiovascular disorder and hypertensive disorder.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: C08CA11
• Indications: 2 conditions
• Clinical trials: 3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1085699
Name	MANIDIPINE 6300
Type	Small molecule
Max phase	3
ATC	C08CA11

Also known as: Artedil, Franidipine, Manidipine, Manidipine 6300, Manidipino, manidipine, SID50112746, SID174006297, MANIDIPINE 6300, MANIDIPINE HYDROCHLORIDE, MANIDIPINE

Parent form; salt/anhydrous children: CHEMBL2362693

Patent coverage: 1,880 distinct patent families (7,701 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 7,683 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 15 (assay-derived). Sample: Nuclear receptor ROR-gamma, D(2) dopamine receptor, Cannabinoid receptor 1, Histamine H1 receptor, D(3) dopamine receptor, Kappa-type opioid receptor, Sodium-dependent dopamine transporter, Voltage-gated inwardly rectifying potassium channel KCNH2, Adenosine receptor A3, Androgen receptor.

Bioactivity

ChEMBL activities: 13 potent at pChembl ≥ 5 of 16 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P22002	6.52	AC50	300	nM	CHEMBL_ACT_25119477
KCNH2	6.09	AC50	820	nM	CHEMBL_ACT_25117659
HRH1	5.43	AC50	3700	nM	CHEMBL_ACT_25212359
ADORA3	5.42	AC50	3800	nM	CHEMBL_ACT_25134061
ABCB1	5.34	IC50	4600	nM	CHEMBL_ACT_11001475
ABCB1	5.33	IC50	4650	nM	CHEMBL_ACT_11001474
P25779	5.22	IC50	6000	nM	CHEMBL_ACT_3307710
DRD3	5.2	AC50	6300	nM	CHEMBL_ACT_25193380
DRD2	5.18	AC50	6600	nM	CHEMBL_ACT_25140181
Q63921	5.13	AC50	7400	nM	CHEMBL_ACT_25174249
OPRK1	5.1	AC50	7900	nM	CHEMBL_ACT_25129294
NR1I2	5.1	AC50	7900	nM	CHEMBL_ACT_25188081
P15207	5.09	AC50	8100	nM	CHEMBL_ACT_25232789

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
cardiovascular disorder	3	MONDO:0004995	EFO:0000319
hypertensive disorder	3	MONDO:0005044	EFO:0000537

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE4	1
PHASE3	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03106597	PHASE4	TERMINATED	Manidipine Versus Amlodipine in Patients With Hypertension
NCT00627952	PHASE3	COMPLETED	A Study to Evaluate the Effects of Manidipine Versus Amlodipine and the Combination of Manidipine Plus Delapril Versus Amlodipine Plus Delapril on Intraglomerular Pressure in Hypertensive Patients
NCT07091136	PHASE2	NOT_YET_RECRUITING	Exploration of Manidipine to Reverse Aortic Valve Calcification

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).